List view / Grid view

Erik Ryberg (AstraZeneca R&D)

 

article

Building GPCR screening cascades for lead generation

6 May 2014 | By , , ,

Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…